Can-Fite Obtains Patent in Korea for Treatment of Psoriasis

Can-Fite BioPharma (NYSE:CANF) announced it obtained a patent from the Korean Intellectual Property Office for the Company’s lead drug candidate Piclidenoson (CF101) in its psoriasis indication.
As quoted in the press release:

Can-Fite has two distribution agreements in Korea including one with Kwang Dong Pharmaceutical for Piclidenoson in the treatment of rheumatoid arthritis and another with Chong Kun Dang for Namodenoson in the treatment of liver cancer.
“Korea is an important market for us, as evidenced by the two distribution agreements we already have there. This patent may increase the value of a potential distribution deal in Korea for Piclidenoson in the treatment of psoriasis,” stated Can-Fite CEO Dr. Pnina Fishman. “We believe Piclidenoson is a strong candidate for the treatment of moderate to severe psoriasis due to its excellent safety profile for long-term use and its favorable comparison with Otezla, the leading oral therapy currently on the market.”

Click here to read the full press release.

Source: www.businesswire.com